San Francisco Bay area adult glioma survival study

旧金山湾区成人神经胶质瘤生存研究

• 批准号: 7550492
• 负责人: Margaret Wrecsch
• 金额: $ 22.28万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7550492
• 关键词: adult human (21+); alcoholic beverage consumption; clinical research; disease /disorder onset; genetic markers; genetic polymorphism; glioma; human data; human mortality; human subject; neoplasm /cancer epidemiology; neoplasm /cancer genetics; nutrition aspect of cancer; nutrition related tag; prognosis

DESCRIPTION (provided by applicant): The identification of relevant tumor and patient characteristics is likely to aid in choosing the best treatments for each glioma patient, in enhancing definition of homogeneous subgroups for clinical trials based on uniform prognosis for rapid treatment evaluation, and in providing better prognostic information to patients. To identify relevant characteristics, this study will examine survival in relationship to several tumor markers with potential prognostic value, patient characteristics known to be prognostic (such as age), and those factors as yet unstudied in relation to glioma prognosis including a variety of polymorphisms in DNA repair and carcinogen metabolizing genes, personal and family medical histories, diet, smoking and alcohol consumption prior to diagnosis, and other demographic factors. The study's specific aims are to: (1) Determine vital status through 2004 and relevant treatment information or 881 population based adult onset glioma cases diagnosed between 1991-94 and 1997-99 and interviewed as part of the San Francisco Bay Area Adult Glioma Study (an ongoing NCI funded study of the genetic and molecular epidemiology of adult glioma). (2) Use Cox regressions and recursive partitioning analysis to determine survival as a function of both established, potential, and as yet unstudied prognostic indicators; (3) Validate results obtained from aim 2 in newly diagnosed GM patients on clinical trial protocols at UCSF. We will collect blood, buccal and tumor specimens and clinical and brief questionnaire data for newly diagnosed patients seen at the UCSF Neuro-Oncology Service from July 1, 2002-June 30, 2006. Promising markers identified in aim 2 will be assayed for 100 of these GM cases on clinical trial protocols and incorporated into a validation survival analysis. This study provides a unique opportunity to examine survival in a large, population-based group of patients with epidemiologic risk factor data, constitutive DNA specimens, and tumor marker data and thus to preliminarily evaluate markers that will then be incorporated into prospective clinical trials for validation.

描述（由申请人提供）：相关肿瘤和患者特征的识别可能有助于为每个胶质瘤患者选择最佳治疗，基于快速治疗评价的统一预后增强临床试验同质亚组的定义，并为患者提供更好的预后信息。为了确定相关特征，本研究将研究生存率与几种具有潜在预后价值的肿瘤标志物的关系，（如年龄），以及尚未研究的与神经胶质瘤预后有关的因素，包括DNA修复和致癌物代谢基因中的各种多态性，个人和家族病史，诊断前的饮食，吸烟和饮酒，和其他人口因素。该研究的具体目的是：（1）确定到2004年的生命状态和相关的治疗信息，或881例1991-94年和1997-99年诊断的成人发病胶质瘤病例，并作为旧金山弗朗西斯科湾区成人胶质瘤的一部分进行访谈 研究（一项正在进行的NCI资助的成人胶质瘤遗传和分子流行病学研究）。(2)使用考克斯回归和递归分割分析来确定生存率作为已建立的、潜在的和尚未研究的预后指标的函数;（3）在UCSF临床试验方案中新诊断的GM患者中从目标2获得的结果。我们将收集2002年7月1日至2006年6月30日在UCSF神经肿瘤服务中心就诊的新诊断患者的血液、口腔和肿瘤标本以及临床和简要问卷调查数据。将在临床试验方案中对100例这些GM病例进行目标2中确定的有希望的标记物测定，并将其纳入验证生存分析。这项研究提供了一个独特的机会，可以通过流行病学风险因素数据、组成性DNA样本和肿瘤标志物数据来检查大量基于人群的患者的生存率，从而初步评估标志物，然后将其纳入前瞻性临床试验中进行验证。